Literature DB >> 18702104

Circulating soluble endoglin and placental abruption.

Caroline Signore1, James L Mills, Cong Qian, Kai F Yu, Sarosh Rana, S Ananth Karumanchi, Richard J Levine.   

Abstract

OBJECTIVE: Our objective was to investigate whether serum concentrations of a novel anti-angiogenic factor, soluble endoglin (sEng), could predict placental abruption.
METHODS: In a nested case-control study of nulliparous pregnancies, we examined levels of sEng in serum collected prospectively from 31 women who later developed placental abruption and from 31 normal controls. All serum specimens were collected before the onset of hypertension or abruption and before labor or delivery. Serum sEng was compared within three gestational age intervals: early- (<20 weeks), mid- (21-32 weeks), and late (>or=33 weeks) pregnancy.
RESULTS: There was no significant difference in sEng between abruption cases and controls in early pregnancy. sEng was significantly elevated among abruption cases at 21-32 weeks (10.7 vs 5.9 ng/mL, P < 0.01). Subgroup analyses revealed no differences in sEng concentrations at any gestational age interval between cases with abruption without hypertension and healthy controls. Among women who developed hypertension and placental abruption, sEng was not significantly increased in early pregnancy, but was in mid-pregnancy (19.3 vs 5.5 ng/mL, P = 0.002) and in late pregnancy (15.6 vs 9.5 ng/mL, P = 0.04).
CONCLUSIONS: Serum levels of the anti-angiogenic factor sEng are elevated prior to the development of hypertension and placental abruption. These elevations are not apparent until the late second trimester (26-27 weeks, on average), but they persist from this time in gestation onward. sEng may be useful for identifying pregnant women at risk for abruption and hypertension. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18702104      PMCID: PMC2574843          DOI: 10.1002/pd.2065

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  20 in total

1.  Placental abruption and its association with hypertension and prolonged rupture of membranes: a methodologic review and meta-analysis.

Authors:  C V Ananth; D A Savitz; M A Williams
Journal:  Obstet Gynecol       Date:  1996-08       Impact factor: 7.661

2.  Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods.

Authors:  R J Levine; J R Esterlitz; E G Raymond; R DerSimonian; J C Hauth; L Ben Curet; B M Sibai; P M Catalano; C D Morris; J D Clemens; M G Ewell; S A Friedman; R L Goldenberg; S L Jacobson; G M Joffe; M A Klebanoff; A S Petrulis; J G Rigau-Perez
Journal:  Control Clin Trials       Date:  1996-10

3.  Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants.

Authors:  I Caniggia; C V Taylor; J W Ritchie; S J Lye; M Letarte
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

4.  Placental abruption in the United States, 1979 through 2001: temporal trends and potential determinants.

Authors:  Cande V Ananth; Yinka Oyelese; Lami Yeo; Archana Pradhan; Anthony M Vintzileos
Journal:  Am J Obstet Gynecol       Date:  2005-01       Impact factor: 8.661

5.  Abruptio placentae. A "classic" dedicated to Elizabeth Ramsey.

Authors:  T K Eskes
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1997-12       Impact factor: 2.435

6.  Birth-weight-for-gestational-age patterns by race, sex, and parity in the United States population.

Authors:  J Zhang; W A Bowes
Journal:  Obstet Gynecol       Date:  1995-08       Impact factor: 7.661

7.  Placental abruption among singleton and twin births in the United States: risk factor profiles.

Authors:  C V Ananth; J C Smulian; K Demissie; A M Vintzileos; R A Knuppel
Journal:  Am J Epidemiol       Date:  2001-04-15       Impact factor: 4.897

8.  Circulating angiogenic factors and the risk of preeclampsia.

Authors:  Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

9.  Placental bed biopsies in placental abruption.

Authors:  J Dommisse; A J Tiltman
Journal:  Br J Obstet Gynaecol       Date:  1992-08

10.  Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies.

Authors:  Robert N Taylor; Jane Grimwood; Rennae S Taylor; Michael T McMaster; Susan J Fisher; Robyn A North
Journal:  Am J Obstet Gynecol       Date:  2003-01       Impact factor: 8.661

View more
  13 in total

1.  Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth.

Authors:  Roselyne Castonguay; Eric D Werner; Robert G Matthews; Eleonora Presman; Aaron W Mulivor; Nicolas Solban; Dianne Sako; R Scott Pearsall; Kathryn W Underwood; Jasbir Seehra; Ravindra Kumar; Asya V Grinberg
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

Review 2.  Angiogenic factors in preeclampsia: potential for diagnosis and treatment.

Authors:  Arvind Goel; Sarosh Rana
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-11       Impact factor: 2.894

3.  New-onset maternal gestational hypertension and risk of retinopathy of prematurity.

Authors:  Mohamed A Zayed; Abhineet Uppal; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-12       Impact factor: 4.799

4.  Midpregnancy levels of angiogenic markers in relation to maternal characteristics.

Authors:  Renée S Mijal; Claudia B Holzman; Sarosh Rana; S Ananth Karumanchi; Jianling Wang; Alla Sikorskii
Journal:  Am J Obstet Gynecol       Date:  2010-12-10       Impact factor: 8.661

5.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Samuel S Edwin; Ricardo Gomez; Lami Yeo; Agustin Conde-Agudelo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

Review 6.  Angiogenic factors and preeclampsia.

Authors:  Sharon E Maynard; S Ananth Karumanchi
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

Review 7.  Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.

Authors:  Camille E Powe; Richard J Levine; S Ananth Karumanchi
Journal:  Circulation       Date:  2011-06-21       Impact factor: 29.690

Review 8.  New developments in the pathogenesis of preeclampsia.

Authors:  Mihran V Naljayan; S Ananth Karumanchi
Journal:  Adv Chronic Kidney Dis       Date:  2013-05       Impact factor: 3.620

9.  Maternal Cardiovascular and Cerebrovascular Health After Placental Abruption: A Systematic Review and Meta-Analysis (CHAP-SR).

Authors:  Cande V Ananth; Haylea S Patrick; Srinidhi Ananth; Yingting Zhang; William J Kostis; Meike Schuster
Journal:  Am J Epidemiol       Date:  2021-12-01       Impact factor: 5.363

10.  Response to Plasmapheresis Measured by Angiogenic Factors in a Woman with Antiphospholipid Syndrome in Pregnancy.

Authors:  Karoline Mayer-Pickel; Sabine Horn; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Case Rep Obstet Gynecol       Date:  2015-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.